<DOC>
	<DOCNO>NCT00955825</DOCNO>
	<brief_summary>The purpose study assess efficacy safety 300 IR sublingual tablet grass pollen allergen extract compare placebo adult patient allergic rhinoconjunctivitis .</brief_summary>
	<brief_title>Study Efficacy Safety 300 IR Sublingual Immunotherapy ( SLIT ) Tablets Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description>Allergy one common chronic disease world currently affect 10 % 25 % general population . Allergies pollens characteristically result seasonal rhinitis symptom allergic rhinoconjunctivitis characterize sneezing , congestion , rhinorrhea , nasal palatal itching itchy , watery , red swollen eye . Even several drug effectively manage allergic rhinoconjunctivitis symptom , immunotherapy consider appropriate patient symptom optimally control relief medication . In study , six rhinoconjunctivitis symptom ( sneeze , runny nose , itchy nose , nasal congestion , itchy eye , watery eye ) evaluate daily relief medication intake ( oral antihistamine , eye drop antihistamine , nasal corticosteroid , oral corticosteroid ) report daily grass pollen season . Efficacy good safety profile 300IR SLIT tablet administer per day approximately six month ( start 4 month season ) demonstrate grass pollen season compare placebo .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>1 . Grass pollenrelated allergic rhinoconjunctivitis least last two pollen season . 2 . Positive SPT grass 3 . Total symptom score previous pollen season 12 18 . 4 . Patients FEV1 â‰¥ 80 % predict value . 1 . Positive SPT grass present grass pollen season endemic region 2 . Patients clinically significant confound symptom allergy allergen potentially overlap grass pollen season 3 . Asthma require treatment medication beta2 inhaled agonist . 4 . Patients receive desensitization treatment grass pollen past 5 year . 5 . Ongoing immunotherapy allergen . 6 . Patients nasal oral condition could confound efficacy safety assessment 7 . Patients known history hypersensitivity intolerance excipients investigational product ( lactose intolerance ) . 8 . Patients past current clinically significant condition judge investigator , may affect patient 's participation outcome study . 9 . Patients treat systemic inhaled corticosteroid 10 . Patients treat treatment betablockers , continuous systemic corticotherapy immunosuppressive drug . 11 . Pregnant , breastfeeding , sexually active woman use medically accept contraceptive method list . 12 . Patients participate participate within 30 day Screening clinical study . 13 . Patients unlikely complete study reason , patient travel extend period time grass pollen season compromise data 14 . Patients history drug alcohol abuse . 15 . Study staff , investigator , subinvestigators , well child spouse family member study staff enrol study . 16 . Patients randomize study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>allergic rhinoconjunctivitis</keyword>
</DOC>